No pipeline data
No cash flow data
No capital raise or buyback data
Historical delivery and spending consistency. Data is limited for recently added companies.
Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.
These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.
| Event | Type | Confidence | Impact | Date | Status |
|---|---|---|---|---|---|
| US patent grants for NTI164open_in_new The two US patent applications covering methods of reducing neuroinflammation and treating autism spectrum disorder using NTI164 are expected to be formally granted, providing IP protection through to 2042. [Source: NTI secures Notices of Allowance for US patent applications, 2026-07-01] | regulatory decision | Expected | removeMed | 31 Dec 2027 | Upcoming |
| Loan maturity dateopen_in_new The $3.15 million R&D tax incentive loan from Rockford RDF matures on 31 December 2027. [Source: Neurotech secures $3.15 million R&D tax incentive loan, 2026-07-15] | commercial milestone | Confirmed | removeMed | 31 Dec 2027 | Upcoming |
| Phase III clinical studies in ASDopen_in_new Loan proceeds will fund Phase III clinical studies in autism spectrum disorder, expected to commence following this funding announcement. [Source: Neurotech secures $3.15 million R&D tax incentive loan, 2026-07-15] | data readout | Expected | arrow_upwardHigh | 31 Dec 2027 | Upcoming |
| NTI164 Other — Secondary Trading Noticeopen_in_new This announcement is a secondary trading notice pursuant to Section 708A(5)(e) of the Corporations Act, relating to the issuance of ordinary fully paid shares. It does not contain any regulatory milestone or designation information. | regulatory decision | Confirmed | removeMed | 21 July 2026 | Completed |
| Neurotech secures $3.15 million R&D tax incentive loanopen_in_new Neurotech secured a $3.15 million non-dilutive loan from Rockford RDF against anticipated R&D tax incentive refunds for FY2026-FY2027. The facility carries a 16% interest rate with a maturity date of 31 December 2027, and proceeds will fund Phase III clinical studies in ASD, ongoing R&D, and working capital. | other | Confirmed | Med |
| 15 July 2026 |
| Completed |
| NTI164 FDA — US FDA clears IND for NTI164open_in_new The US FDA cleared Neurotech International's Investigational New Drug (IND) application for NTI164, authorising the commencement of a proposed US clinical development program including a population pharmacokinetic (PopPK) study. This milestone establishes a formal US clinical development pathway to support potential future FDA registration as part of an integrated global strategy alongside Neurotech's Australian Phase 3 'Beyond Harmony' trial. | regulatory decision | Confirmed | removeMed | 13 July 2026 | Completed |
| Proposed issue of securities - NTIopen_in_new | financing | Confirmed | removeMed | 12 July 2026 | Completed |
| NTI164 USPTO — NTI secures Notices of Allowance for US patent applicationsopen_in_new The USPTO has issued Notices of Allowance for two U.S. patent applications covering methods of reducing neuroinflammation and treating autism spectrum disorder using NTI164. Once formally granted, these patents are expected to provide intellectual property protection for NTI164 through to 2042. | regulatory decision | Confirmed | removeMed | 1 July 2026 | Completed |